Pages

Monday, February 6, 2012

Law suit says Pfizer hid birth defect risks to pregnant mothers

Feb. 6, 2012, 3:49 p.m. EST
St. Louis-based Carey, Danis & Lowe Announces Suit Against the Maker of Zoloft
Alleges Pfizer hid birth defect risks to pregnant mothers prescribed the antidepressant

ST. LOUIS, Feb 06, 2012 (BUSINESS WIRE) -- St. Louis--based law firm Carey, Danis & Lowe announces the filing of a lawsuit on behalf of 18 plaintiffs against Pfizer PFE +0.05% , maker of the antidepressant drug Zoloft.

Zoloft (generic name sertraline) belongs to a class of drugs known as selective serotonin reuptake inhibitors, or SSRIs. The U.S. Food and Drug Administration has approved Zoloft for the treatment of major depressive disorder, obsessive-compulsive disorder, panic disorder, acute post--traumatic stress disorder, premenstrual dysphoric disorder and social anxiety disorder.

The lawsuit, Shainyah Lancaster, et al. v. Pfizer, Inc., cause no. 1222-CC00766, was filed on Feb. 2 in St. Louis Circuit Court on behalf of 18 children born with defects after their mothers were prescribed Zoloft while pregnant. The suit was brought on behalf of the plaintiffs by the law firms of Carey, Danis & Lowe; Matthews & Associates; Freese & Goss; and Clark, Burnett, Love & Lee.

The suit notes that SSRIs have been found to cause severe birth defects in the children of women who were prescribed the drug while pregnant and alleges that Pfizer knew or should have known of SSRI studies revealing that children born to mothers who had taken SSRIs during pregnancy had a greater risk of congenital birth defects such as atrial septal defect, multiple holes in the heart and persistent pulmonary hypertension of the newborn. The plaintiffs also allege that Pfizer knew that physicians were prescribing Zoloft to women of childbearing age but failed to adequately warn the medical community and the public of the danger.
read more here

No comments:

Post a Comment

If it is not helpful, do not be hurtful. Spam removed so do not try putting up free ad.